AGP Executive Report
Last update: 8 hours agoMedicaid Coverage Cuts: Rhode Island Medicaid will stop covering Wegovy, Zepbound, Saxenda, and Foundayo when prescribed only for weight loss starting Oct. 1, 2026—while GLP-1s for Type 2 diabetes remain covered. The change follows other states’ cutbacks and could mean list-price costs topping $1,000 a month for some patients. Health System Partnership: South County Health in Wakefield has joined the Mayo Clinic Care Network, becoming the first Rhode Island provider (and only the second in New England) to access Mayo’s clinical, educational, and research resources—without changing ownership or control. Respiratory Season Watch: Rhode Island is entering fall with low COVID-19, flu, and RSV levels, though COVID-19 is rising from summer lows; updated immunizations are available statewide. Alzheimer’s Fundraiser: The Alzheimer’s Association will host a Walk to End Alzheimer’s in Westerly, highlighting support for the roughly 22,000 Rhode Islanders living with Alzheimer’s and 37,000 caregivers. Drug Pricing Accountability: Iowa joined a multistate coalition seeking court approval of a $400 million settlement with Sandoz and Fougera over alleged generic-drug price manipulation, with Rhode Island included in the broader enforcement effort. Data Privacy: A class action investigation is underway after a reported data breach at Atlantic Digestive Specialists, with at least 51 Rhode Island residents reportedly notified. Public Health Access: Rhode Island’s Medicaid and health coverage changes come as New England faces broader coverage pressures, including upcoming Medicaid benefit losses for some immigrants.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
